[Physiopathology of cerebral ischemia: what is the contribution of future treatments?].
Deplanque
D
D
Département de Pharmacologie médicale-EA 1046, Faculté de Médecine, Université de Lille 2 et CHU, Lille. dominique.deplanque@univ-lille2.fr
D000138:Acidosis / Q000150:complications; D017209:Apoptosis; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D004921:Erythropoietin / Q000627:therapeutic use; D005334:Fever / Q000150:complications; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D017202:Myocardial Ischemia / Q000473:pathology / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D004921:Erythropoietin; D010959:Tissue Plasminogen Activator